TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02919878
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
Study: NCT04187352
Drug: CS1001+ Fluorouracil+Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CS1001 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle.
Study: NCT04187352
Drug: Placebo+ Fluorouracil+Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo 1200 mg, intravenous infusion on the first day of each cycle (3 weeks) (Q3W).~Fluorouracil: 800 mg/m2/day, continuous intravenous infusion on Day 1 to Day 4 of each cycle Cisplatin: 80 mg/m2, intravenous infusion on the first day of each cycle.
Study: NCT03282916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sugar pill 500mg caplet
Study: NCT00482430
Drug: MK0557
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0557 10mg tablet qd for a 15-wk treatment period
Study: NCT00482430
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0557 Pbo tablet qd for a 15-wk treatment period
Study: NCT02529787
Drug: Doxirazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule contains 60 mg Dexlansoprazole
Study: NCT00859430
Drug: Keppra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Tablet
Study: NCT01576549
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT00999232
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
Study: NCT00999232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
Study: NCT00003715
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003715
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00722124
Drug: S-Adenosyl-L-Methionine
Normalized name: S-Adenosyl-L-Methionine (Sam-E)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg dose per day for 8 weeks
Study: NCT00722124
Drug: S-Adenosyl-L-Methionine
Normalized name: S-Adenosyl-L-Methionine (Sam-E)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg per day for 8 weeks
Study: NCT03294785
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
Study: NCT03421834
Drug: Optimal medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal guidelines-based heart failure treatment and antiarrhythmic drugs. Antiarrhythmics will be avoided if possible in the ablation group.
Study: NCT00730938
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of Ringers lactate
Study: NCT01294787
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00097344
Drug: Aromatase inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00097344
Drug: Estrogen receptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01830504
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment.
Study: NCT00027053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02071303
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg will be given to 70 women before the procedure.
Study: NCT02071303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be given to 70 women before the procedure.
Study: NCT01725529
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
Study: NCT01725529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules taken orally with food once-daily for 48 weeks.
Study: NCT00133991
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1500 mg/m\^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.
Study: NCT00133991
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 g/m\^2 on Day 8 of each cycle of R-CVP.
Study: NCT02997202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01199133
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One sublingual tablet daily for one year.
Study: NCT00133991
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
Study: NCT00133991
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.
Study: NCT00634309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02334449
Drug: LML134
Approvals — FDA: no, EMA: no, PMDA: no
Description: LML134 will be administered first as single doses and then as multiple doses
Study: NCT02334449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All study cohorts (except food effect cohort) are placebo controlled
Study: NCT01686451
Drug: XueZhiKang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
Study: NCT01686451
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 20mg of simvastatin daily for 4 weeks.
Study: NCT01452815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.
Study: NCT01107093
Drug: CDB-2914 (ulipristal acetate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 30 mg
Study: NCT01107093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT01669070
Drug: FF, 50 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel dry powder inhaler
Study: NCT01669070
Drug: FF, 100 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel dry powder inhaler
Study: NCT00079625
Drug: Th2/Tc2 Cells
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01310647
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle
Study: NCT01669070
Drug: FF, 200 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel dry powder inhaler
Study: NCT01669070
Drug: FF, 250 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT01310647
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
Study: NCT01310647
Drug: CombEq
Approvals — FDA: no, EMA: no, PMDA: no
Description: (150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.~Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle.
Study: NCT02055963
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
Study: NCT02055963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
Study: NCT00547846
Drug: PDC-748
Normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03491072
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive IV fentanyl
Study: NCT00267670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill PO TID
Study: NCT00785629
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02821507
Drug: sirolimus and cyclophosphamide
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00785629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04408079
Drug: TQB3558
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3558 is a kinase inhibitor of the TRK protein family.
Study: NCT02339207
Drug: AL-335 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01880931
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The effect site concentration of remifentanil
Study: NCT02517684
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00225030
Drug: antihypertensive drugs according to current guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02648906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02517684
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00946374
Drug: Immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
Study: NCT00946374
Drug: High-dose BEAM plus autologous SCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( \> 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
Study: NCT00935480
Drug: Isentress®
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.O, 1 tablet containing 400 mg every 12 hours
Study: NCT00935480
Drug: Celsentri®
Approvals — FDA: no, EMA: no, PMDA: no
Description: p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
Study: NCT02290873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive control arm
Study: NCT04089735
Drug: APP13007 Placebo, 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: APP13007 placebo eyedrop, 0.1%
Study: NCT01108029
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of placebo 1 time a day in the morning
Study: NCT01230541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily, oral tablet
Study: NCT00577642
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
Study: NCT01755078
Drug: Calcium-based phosphate binder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01747642
Drug: Suranix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
Study: NCT02595476
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00725569
Drug: Bellis perennis and Staphysagria (C6)
Approvals — FDA: no, EMA: no, PMDA: no
Description: homeopathic remedy
Study: NCT00725569
Drug: Bellis perennis and Staphysagria (C30)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic Remedy
Study: NCT00725569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo remedy, identical in size, shape and taste to treatment remedies
Study: NCT01443520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be given orally placebo twice a day for 8 days prior to the study.
Study: NCT00736255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
Study: NCT01841944
Drug: Pikasol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
Study: NCT01183143
Drug: GONAL-f®
Approvals — FDA: no, EMA: no, PMDA: no
Description: GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
Study: NCT03370783
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol consumption
Study: NCT00239798
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04135235
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol tenofovir fumarate
Study: NCT01530880
Drug: Intravenous Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
Study: NCT01530880
Drug: Acetaminophen (Standard of Care)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T\>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
Study: NCT01424124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, one times daily / 7 days
Study: NCT02241759
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00762060
Drug: Patient controlled analgesia
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV opioids delivered via PCA
Study: NCT02531581
Drug: NaCl 9% isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 500 cc / 4 hours and 1 L / 24 hours
Study: NCT01601028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
Study: NCT01338831
Drug: LFA102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01627158
Drug: Symbicort Turbuhaler
Normalized name: Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort Turbuhaler
Study: NCT01627158
Drug: Charcoal and Symbicort Turbuhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Charcoal and Symbicort Turbuhaler
Study: NCT01646554
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00834249
Drug: Effexor® 25 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 25 mg, single-dose fasting
Study: NCT03913559
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal (IT) therapy
Study: NCT03913559
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intrathecal (IT) therapy
Study: NCT03913559
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg (max 650 mg) PO x 1
Study: NCT03644147
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen will be intravenously administrated to treatment group after the end of surgery.
Study: NCT02466152
Drug: GSK2894512 Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram \[mg/g\]) and 1.0% (10 mg/g)
Study: NCT01013077
Drug: Optive
Normalized name: optive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use a minimum of 2 drops per day for 1 month.
Study: NCT01370356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
Study: NCT01143753
Drug: RO5212054
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.
Study: NCT01392534
Drug: Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study: NCT00754832
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
Study: NCT02004262
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
Study: NCT02004262
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00808795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
Study: NCT02813551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02055820
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
Study: NCT02055820
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
Study: NCT01032915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo s.c weekly for 3 weeks then every 2 weeks
Study: NCT04173988
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for lymphodepletion
Study: NCT02915523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A pill containing no active drug ingredient.
Study: NCT03977272
Drug: Combination drug
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly
Study: NCT03977272
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified-FOLFIRINOX
Study: NCT01247701
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
Study: NCT00882063
Drug: P276-00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
Study: NCT01217632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.
Study: NCT00431340
Drug: PXD101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01204437
Drug: Epirubicin, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22
Study: NCT01204437
Drug: Cyclophosphamide, Methotrexate, 5 FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)